<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755350</url>
  </required_header>
  <id_info>
    <org_study_id>NON-SSC NO. 456</org_study_id>
    <secondary_id>OPP1104919</secondary_id>
    <nct_id>NCT02755350</nct_id>
  </id_info>
  <brief_title>Introducing PrEP Into HIV Combination Prevention - Kenya</brief_title>
  <acronym>IPCP-Kenya</acronym>
  <official_title>Demonstrating Effective Delivery of Daily Oral HIV Pre-Exposure Prophylaxis as Part of HIV Combination Prevention Intervention Among Young Women at High HIV Risk, Female Sex Workers and Men Who Have Sex With Men in Kenya (IPCP-KENYA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LVCT Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sex Workers Outreach Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National AIDS Control Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National AIDS and STI Control Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Options for Young Men with AIDS/STI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bar Hostess Empowerment &amp; Support Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gay and Lesbian Coalition Kenya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ISHTAR MSM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenya Sex Workers Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Results for Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>O' Neill Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AVAC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nyanza Western Kenya LGBTI Coalition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centres for Disease Control and Prevention, Kenya.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LVCT Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Daily oral PrEP will be delivered to men who have sex with men (MSM), female sex workers
      (FSWs) and young women (YW) as part of a defined package of HIV combination prevention
      intervention for 12 months in 5 sites in Kenya. The project will assess adherence, adverse
      events, side effects, user satisfaction, cost, facility preparedness and provider
      competencies. PrEP eligibility and screening tools for MSM, YW and FSWs will be piloted and
      validated. Pregnant women will be enrolled in a sub-group and followed through 12 months
      post- partum to measure mother and infant outcomes that include health status, birth
      outcomes, birth defects, risk behavior and PrEP adverse effects. With lessons from initial
      PrEP studies in West and Central Africa, this project will apply good participatory practice
      guidelines through 1) continuous engagement with communities of FSWs, YW and MSM and 2)
      development and use of a communication engagement and advocacy strategy that will provide
      correct information, address attitudes and concerns whilst increasing demand for PrEP uptake.
      The actual cost of delivering HIV combination prevention which includes PrEP will also be
      assessed and cost effectiveness modeled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project will be undertaken in 3 counties of Kenya (Nairobi, Kisumu and Homa Bay) that
      have high HIV prevalence. 5 sites (2 government and 3 non-governmental) have been purposively
      selected for the demonstration because they serve high risk populations, have existing HIV
      prevention services and have adequate cohort of HIV negative clients who are potential
      candidates for PrEP. The sites include LVCT Health's Nairobi CBD and Tivoli sites, SWOP City
      clinic, Homa Bay County Referral Hospital and Korogocho Health Centre. The demonstration
      project will use a prospective cohort design employing mixed-methods. A cohort of 2100 PrEP
      users (female sex workers aged 18 and above, men who have sex with men aged 18 and above,
      young women at high HIV risk aged 15 -29) will be followed over 12 months to assess
      biological and behavioral outcomes through laboratory and survey assessments. This will be
      complemented by review of routine service delivery statistics (to assess PrEP uptake), cost
      data, and qualitative data to be obtained from in-depth interviews and focus groups with
      health providers, PrEP users, and peer educators/community health workers at multiple points
      in time.This project will be implemented in a 'real life' or 'real world' setting where there
      will be no control or comparison arms. However, pregnant women at enrolment and female
      participants who become pregnant during project implementation, who choose to continue on
      PrEP will be enrolled in a sub-group and followed through 12 months post-partum.

      Activities to be undertaken prior and during project implementation:

        -  HIV prevention packages, provider training, quality management and service delivery
           guidelines and standard operating guidelines will be developed.

        -  PrEP eligibility and screening tools for target populations will be piloted and
           validated prior to project implementation. For young women, a test of understanding will
           be additionally administered to screen for eligibility.

        -  Community sensitization and demand creation activities will be conducted prior to and
           during implementation. Existing peer educators for FSW and MSM from each site will reach
           out to these populations through hot spots. For young women at high HIV risk, outreach
           activities will be done by peer educators and community health volunteers (CHVs) through
           1) community-based organizations which work with young women (such as youth groups,
           organised social gatherings [chamas], [government administrative meetings such as chief
           barazas] 2) political leaders such as women representatives 3) existing services
           reaching sexually active young women such as family planning, maternal-child health
           (MCH) 4) community radio and 5) anywhere that young women gather such as water points.

        -  To ensure adherence to good participatory practice guidelines (GPP) that outline
           community engagement in clinical and research activities, a national community advisory
           board (CAB) and community advisory committees (CAC) at each project site will be formed.
           The CAB and CACs will participate in the development and execution of demand creation
           activities, development of community education materials, peer education and
           mobilization, strategy development, project design, implementation and advocacy.

      Project procedures:

      At the screening visit, eligible and willing participants will be provided with full
      information about PrEP, results of efficacy trials, known side effects and potential adverse
      events, and daily dosing schedule. They will receive counselling on adherence to PrEP
      including discussions between PrEP users and service providers on developing new routines and
      cues as a way to facilitate good adherence. They will also receive detailed information about
      the project, including the number and sequence of project visits, procedures at each visit,
      use of MEMS Caps, and the option to discontinue PrEP use during the course of the project.
      They will also be counselled on available combination prevention strategies such as condom
      use and provided with free condoms. Participants will also be informed that PrEP will only be
      available for 12 months.

      Willing participants will sign an informed consent form, and complete a survey questionnaire
      to provide baseline information on their demographics, sexual risk behaviours, risk
      perceptions, medical history, alcohol and drug use, contraceptive use, fertility intentions,
      and use of other combination HIV prevention services. They will receive HIV testing and
      counselling (HTC), tests for Hepatitis B surface antigen, STI syndromic screening and
      management as well as testing for gonorrhoea, blood draw for creatinine level and pregnancy
      test where applicable. Individuals who test HIV positive are ineligible for the project and
      will be referred to care and treatment according to standard practice. Pregnant women and
      women who become pregnant during the project implementation will be enrolled in a pregnancy
      sub group, upon their consent. Those who decline participation will receive referrals to
      prenatal care.

      Participants will return to the project site after 14 days (2 weeks), for an enrolment visit
      where they will receive a one month PrEP prescription, a HIV re-test and counselling on
      adherence, side effects, and available supportive interventions. Participants will be asked
      to return after 2 weeks for assessment of adherence and side effects. They will then return
      to the site for the first follow up visit (1 month after enrollment visit) where they will
      receive the following services: counselling on HIV risk behaviours, adherence, side
      effects/experience with PrEP, HTC, pregnancy test (for women), creatinine level test, STI
      syndromic screening and management, gonorrhoea test, drug level testing, and PrEP
      prescription for one month (with refills from pharmacy at months 2 and 3). Every 10th
      participant will complete a quantitative survey at exit.

      Participants will then return to the site for a quarterly visit at months 4, 7, and 10 after
      enrolment. The services provided during these visit will be similar to those at the first
      follow up visit. Participants who display high adherence will be provided with a 3 months'
      supply of PrEP. Those who need close monitoring will be provided with a one month's supply
      and will return for pharmacy refills monthly.

      Participants will finally return for an exit visit, 12 months after enrolment. They will
      receive services similar to those at enrolment. They will also complete an exit survey, and
      discuss post project PrEP access with the health provider.

      Individuals who want to discontinue PrEP use will be allowed to do so, and asked to consent
      for in depth interview to discuss their experience and decision to stop. Those who display
      poor adherence will be discontinued from PrEP. Those who sero-convert will be referred to
      care and treatment services as per standard practice.

      Key strategies for retention will include 1) follow up of participants by peer educators and
      community health volunteers, 2) using text messages for appointment reminders and adherence
      support 3) enrolling participants in support groups, and 4) adherence buddies.

      Indepth interviews with PrEP users and health providers, focus group discussions with peer
      educators, CHWs, and support group members will be conducted at Months 1, 6 and 12. The
      actual cost of implementing HIV combination prevention that includes PrEP will be collected
      throughout the project implementation period.

      Ethical considerations observed in the implementation of this project include protocol
      approval by KEMRI ethics research committee, informed consent for participants,
      confidentiality of participants and their data and ensuring safety of participants.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of young women, female sex workers and men who have sex with men correctly identified as being at high risk of HIV, in need of and willing to take PrEP.</measure>
    <time_frame>4 months</time_frame>
    <description>Validation of tools for risk identification and indication for PrEP initiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of men who have sex with men, female sex workers and young women at high risk of HIV enrolled into a HIV combination prevention intervention package that includes PrEP.</measure>
    <time_frame>4 months</time_frame>
    <description>Validation of tools for risk identification and indication for PrEP initiation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants adhering to oral PrEP as measured using the MEMS cap and MedAmigo system.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants enrolled and retained in a HIV combination prevention package that includes PrEP over a period of 12 months.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of enrolled participants reporting side effects as recorded on the clinical and adverse event forms</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Unit cost analysis of identifying and enrolling clients on PrEP in a 'real world' setting identified through mathematical modelling</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cost estimates for providing PrEP to high risk populations determined through cost models</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of enrolled participants reporting pregnancy complications as recorded on the pregnancy outcome forms</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Truvada</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral PrEP (Truvada) is provided to a cohort of 2100 participants who will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period. In between some visits, they will return to the pharmacy for a refill of PrEP, counselling on adherence and medication of side effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.</description>
    <arm_group_label>Truvada</arm_group_label>
    <other_name>Pre Exposure Prophylaxis (PrEP)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Self-reported interest in and willingness to take PrEP

          -  Score cut-off on PrEP screening tool

          -  HIV- negative test at time of enrollment (per testing algorithm)

          -  No clinical symptoms of acute HIV infection including fever, lymphadenopathy,
             pharyngitis, skin rash, myalgias/arthralgias.

          -  Hepatitis-B virus antigen negative (upon screening)

          -  Creatinine clearance â‰¥ 60ml/min (Cockcroft-Gault formula) (upon screening)

          -  Not breastfeeding

          -  Not currently taking PrEP or enrolled in another PrEP demonstration project

          -  Willingness to visit the project site of choice for follow up visits throughout the
             project period

          -  Knowledge of spoken English or Kiswahili

          -  Is in good general health and does not report a medical condition which may make their
             participation unsafe.

          -  Is not currently taking post exposure prophylaxis (PEP).

          -  Willing to provide contact information and be contacted by project staff between
             visits for follow up and support.

          -  Able to summarise the purpose of the demonstration project and their role as
             participants.

          -  Sexually active - having had sex in the last 3 months

        Specific eligibility criteria for each project population are as follows:

          -  MSM: Age 18 and above; Self-reported anal sex with a man

          -  FSW: Age 18 and above; Self-identification as a sex worker;

          -  Young Women: Aged 15-29 ;Among young women aged 15-17, a test of understanding will
             also be administered to further determine their eligibility.

        Exclusion Criteria:

          -  HIV positive

          -  Breastfeeding

          -  HIV positive

          -  Women above 29 years

          -  Those who fail test of understanding

          -  Those who do not meet the score cut-off on PrEP screening tool

          -  Not sexually active
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serah N Njenga, BA</last_name>
    <role>Principal Investigator</role>
    <affiliation>LVCT Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence J Gelmon, MD.MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sex Workers Outreach Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nduku S Kilonzo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National AIDS Control Council, Kenya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helgar K Musyoki, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>National AIDS and STIs Control Program, Kenya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael K Kiragu, MBChB</last_name>
    <phone>+254 20 2646692, 2633212</phone>
    <phone_ext>1404</phone_ext>
    <email>mkiragu@lvcthealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wanjiru Mukoma, PhD</last_name>
    <phone>+254 20 2646692, 2633212</phone>
    <phone_ext>1507</phone_ext>
    <email>wmukoma@lvcthealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LVCT Health</name>
      <address>
        <city>Nairobi</city>
        <zip>00202</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael K Kiragu, MBChB</last_name>
      <phone>+254 20 2646692, 2633212</phone>
      <phone_ext>1404</phone_ext>
      <email>mkiragu@lvcthealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Wanjiru Mukoma, PhD</last_name>
      <phone>+254 20 2646692, 2633212</phone>
      <phone_ext>1507</phone_ext>
      <email>wmukoma@lvcthealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>April 27, 2016</last_update_submitted>
  <last_update_submitted_qc>April 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PrEP</keyword>
  <keyword>HIV Prevention</keyword>
  <keyword>combination prevention</keyword>
  <keyword>demonstration project</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

